The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes

Table 1

Clinical and biochemical characteristics of patients (𝑛=302).

Characteristics	Values
Age (years)	67.4 ± 7.3
Men/women (𝑛/𝑛)	143/159
Body mass index (kg/m^2)	24.8 ± 3.1
Duration of diabetes (years)	14.6 ± 9.1
Fasting glucose (mg/dL)	151.4 ± 59.4
HbA1C (%)	7.6 ± 1.4
Aspartate transaminase (mg/dL)	23.2 ± 11.5
Alanine transaminase (mg/dL)	21.4 ± 13.7
Serum calcium (mg/dL) [𝑛=174]	9.2 ± 0.6
Serum phosphorus (mg/dL) [𝑛=174]	4.0 ± 0.9
Parathyroid hormone (pg/mL) [𝑛=114]	52.9 [27.5–170.8]
25(OH)D (ng/dL)	35.5 ± 22.7
Serum creatinine (mg/dL)	2.3 ± 2.9
Serum sclerostin (pmol/L)	64.4 [45.4–91.1]
eGFR (ml/min/1.73 m^2)	53.9 ± 26.8
CKD-eGFR categories
G1/2 (≥60 ml/min/1.73 m^2)	149 (49.3%)
G3 (30~59 ml/min/1.73 m^2)	90 (29.8%)
G4/5 (<30 ml/min/1.73 m^2)	63 (20.9%)

Data are shown as mean ± SD or median [interquartile range] as appropriate.